A bstract. Feminization in men occurs when the effective ratio of androgen to estrogen is lowered. Since sufficient estrogen is produced in normal men to induce breast enlargement in the absence of adequate amounts of circulating androgens, it has been generally assumed that androgens exert an antiestrogenic action to prevent feminization in normal men. We examined the mechanisms of this effect of androgens in the mouse breast.
A bstract. Feminization in men occurs when the effective ratio of androgen to estrogen is lowered. Since sufficient estrogen is produced in normal men to induce breast enlargement in the absence of adequate amounts of circulating androgens, it has been generally assumed that androgens exert an antiestrogenic action to prevent feminization in normal men. We examined the mechanisms of this effect of androgens in the mouse breast.
Administration of estradiol via silastic implants to castrated virgin CBA/J female mice results in a doubling in dry weight and DNA content of the breast. The effect of estradiol can be inhibited by implantation of 17#-hydroxy-5a-androstan-3-one (dihydrotestosterone), whereas dihydrotestosterone alone had no effect on breast growth. Estradiol administration also enhances the level of progesterone receptor in mouse breast. Within 4 d of castration, the progesterone receptor virtually disappears and estradiol treatment causes a twofold increase above the level in intact animals. Dihydrotes inhibits estradiol-mediated induction of the progesterone receptor. Dihydrotestosterone also promotes the translocation of estrogen receptor from cytoplasm to nucleus; the ratio of cytoplasmic-to-nuclear receptor changes from 3:1 in the castrate to 1:2 in dihydrotestosteronetreated mice. Thus, the antiestrogenic effect of androgen in mouse breast may be the result of effects of dihydrotestosterone on the estrogen receptor. If so, dihydrotestosterone performs one of its major actions independent of the androgen receptor.
Introduction
Normal men produce -45 ,ug of estradiol each day, a sixth of which is secreted by the testes and the remainder of which is derived from the extraglandular aromatization of circulating androgens (1) . Extraglandular estradiol formation takes place by two mechanisms, one from the direct conversion of testosterone to estradiol and the other from androgens of adrenal origin by the sequence of androstenedione -estrone -estradiol. The function of estradiol in normal men is unknown, but feminization, commonly manifested by gynecomastia, ensues under conditions of relative or absolute estrogen excess (2) .
Relative estrogen excess occurs when the synthesis or action of androgen is impaired but estrogen production is maintained at or near normal (as occurs in testicular regression or in testicular failure when testicular androgen production ceases but the formation of estrogens from adrenal androgens is unimpaired (3, 4] ). Thus, in the absence of the opposing effects of androgen, sufficient estrogen is produced by normal men to result in profound breast enlargement. Alternatively, estrogen production can increase above the normal range either because of enhanced testicular secretion of estradiol (as in certain testicular tumors) (5, 6) or because of increased formation of estrogen in extraglandular sites (as in cirrhosis of the liver) (2, 7). Since the development of feminizing signs is similar in such fundamentally different disorders, Lewin (8) the ratio of androgen to estrogen, a concept that has received support from detailed studies of androgen and estrogen metabolism in men with feminization in diverse clinical states (2, 9) .
The mechanism by which androgen inhibits estrogen action is unknown. Evidence has been developed in the MCF7 cell line that 17,3-hydroxy-5a-androstan-3-one (dihydrotestosterone)' functions as an antiestrogen by binding to the estrogen receptor itself and like certain other antiestrogens, that dihydrotestosterone can act as a weak estrogen in high concentration (10). Alternatively, the antiestrogenic actions of androgen on the embryonic mouse breast (11) and on the rodent uterus (12) appear to be mediated via the androgen receptor, e.g., androgen induces some action at the genomic level that blunts the estrogenic response. To provide insight into the process by which androgens antagonize estrogen action on the breast in mature animals, we investigated the interaction of these two hormones on the mouse breast.
Methods
Materials. [2,4,6,7-3H]Estradiol ( 112 Ci/mmol) and [ 17a-methyl-3H]promegestone (17,21-dimethyl-19 -nor-pregna-4,9-diene-3,20-dione) (77 Ci/mmol) were obtained from New England Nuclear Corp., Boston, MA. Acetyl bovine serum albumin was prepared by acetylation with I'4Clacetic anhydride (New England Nuclear Corp.) (13) . Unlabeled steroids were from Steraloids, Inc., Wilton, NH. Radiolabeled steroids were checked for purity by thin-layer chromatography.
Animals. Virgin female CBA/J mice were obtained from Jackson Laboratories and were studied at 12 wk of age or older. Mice carrying the X-linked testicular feminization gene (tfm) were bred in our laboratory. The mice carrying the tfm gene have been inbred with C57/BL6 mice carrying a coat color marker tabby (ta) that is closely linked to the tfm gene. In experiments utilizing these mice, +tfm/Y males were compared with ta+/ta+ littermate females. In other experiments, ta+/+tfm females were outbred to ++/Y CBA/J males, and the (fm/Y offspring were compared with female littermates that were a mixture of ta+/++ and +tfm/++ genotypes.
Mice were castrated through a posterior incision under ether anesthesia, subjected to a variety of hormone regimens, and killed at appropriate intervals by cervical dislocation. The posterior inguinal mammary glands were excised and, if receptor studies were to be performed, placed in cold (0-40C) buffer. For studies of breast weight and DNA content, each breast was defatted by a 48-h wash in 10 ml of 2:1 chloroform:methanol solution followed by a 24-h wash in 10 ml of ethyl ether (14) . The tissue was then dried in an oven at 50°C for 2 d and weighed. DNA content was determined in the defatted breast tissue by the method of Burton ( 15 Preparation ofmammary gland cytosol and nuclear extract. Excised breast tissue was placed in cold (0-40C) TEGSH buffer (0.01 M Tris, 1.5 mM EDTA, 0.1% monothioglycerol, 10% glycerol, 10 mM sodium molybdate, pH 7.4). In some samples the TEGSH buffer contained 0.4 M KC1. The tissue was washed three times, suspended in appropriate buffer (0.5 ml/mammary gland), and homogenized using three 10-s bursts with a Brinkmann polytron (Brinkmann Instruments, Westbury, NY) at 70% maximum and with 60-s cooling between each burst. The homogenate was then centrifuged at 100,000 g for 60 min and divided into particulate and soluble fractions. The thick lipid layer that floats to the top was pierced with a Pasteur pipette for removal of the cytosolic fraction, which was used as a receptor source.
The particulate pellet was washed three times with TEGSH buffer and suspended in TEGSH containing 0.4 M KCI and homogenized. After 1 h at 0-4°C, the nuclear material was pelleted as previously described and the supernate was utilized as a source for nuclear receptors. Protein content in the cytosol and nuclear extracts was measured by the method of Lowry et al. (17) .
Sucrose gradient analysis. Samples for gradient centrifugation were prepared by incubation of 0.3 ml of nuclear or cytosolic fractions with appropriate concentrations of [3H]estradiol or [3H]promegestone with or without 150-fold excess of nonradioactive steroids for 4 h at 0-4°C. In experiments involving dihydrotestosterone administration and estrogen receptor measurement, maximal binding occurred within 4 h (results not shown). Unbound steroid was removed by the addition of 75 ul of dextran-coated charcoal in TEGSH buffer (50 mg/ml). The mixture was centrifuged, and 0.2 ml of the supernate was applied to 5-ml linear 5-20% sucrose gradients in TEGSH. [14Clalbumin (1, 600 dpm of 14C) was added to the top to serve as an internal marker in some experiments. The gradients were centrifuged for 18 h in a SW50. 1 rotor at 50,000 rpm (250,000 g) at 0°C in a Beckman ultracentrifuge (Beckman Instruments, Spinco Div., Palo Alto, CA). Four-drop fractions were collected from the top of the tube using an ISCO gradient fractionator (Model 640, ISCO, Lincoln, NE) and assayed for radioactivity in 10 ml Budget Solve (Research Products International Corp., Mount Prospect, IL) in a Packard 2650 liquid scintillation counter (Packard Instrument Co., Downers Grove, IL) with an 3H-efficiency of -30% in dual-label counting. The 14C-efficiency in the 3H-channel was 6%. The disintegrations per minute of 3H were calculated from stored quench curves. Sedimentation values were estimated by the method of Martin and Ames (18) , and the areas under the peaks were estimated by the method of Bartlet and Smith (19) . The amount of receptor binding in the peak was calculated as femtomoles per milligram protein.
Competition experiments. Cytoplasmic extracts were incubated with 5 nM [3Hjestradiol and increasing quantities of unlabeled estradiol, dihydrotestosterone, testosterone, 5a-androstane-3I#,17#-diol (3d-androstanediol), or 17ft-hydroxy-5fl-androstan-3-one (5#-dihydrotestosterone) for 18 h at 0-40C. Parallel incubations with I MM unlabeled estradiol were used to determine nonspecific binding. Samples were then analyzed by sucrose gradient centrifugation.
Results
Normal male mice undergo androgen-mediated regression of the breast anlage during embryogenesis, and consequently, breast development is precluded in the male mouse (20) .
Therefore, we either studied virgin female mice or male tfm mice that do not make a functional androgen receptor and as a consequence do not undergo androgen-mediated breast regression during embryogenesis. In preliminary studies we found that the inguinal breasts are easier to dissect free of muscle tissue than are the anterior breasts, and therefore, we utilized the inguinal breasts to study the interaction of androgen and estrogen in breast growth. Groups of female mice were castrated and implanted with varying amounts of estradiol. 2 wk later the inguinal breast pads were removed, defatted and dried, and analyzed for weight and for DNA content (Fig. 1) . Castration caused little change in dry weight or DNA content. Estrogen treatment of the castrated mice caused an increase in both weight and DNA content, but the maximal increase in each parameter (achieved at the 0.5-cm dosage level) was less than twice that of the castrate control.
The implantation of dihydrotestosterone capsules together with 0.5 cm estradiol capsules prevented the estradiol-mediated enhancement in the dry weight and DNA content of the breast (Fig. 2) . All doses of dihydrotestosterone examined inhibited the effect of estrogen, whereas dihydrotestosterone alone had no measurable effects on the breast even at doses as high as 1.0 cm for 2 wk (results not shown). We concluded that dihydrotestosterone does act as an antiestrogen in the breast of the female mouse, but the findings in regard to both growth and DNA content were significant only at the P . 0.05 level. The lack of more clear-cut effects of dihydrotestosterone is almost certainly due to the fact that the mammary epithelium constitutes only a fraction of the defatted mammary pad, along with defatted adipocytes and fibroblasts (21) . Therefore, we sought another index of the estrogen effect on the breast to utilize in the study of estrogen and androgen interaction. Fig. 1 .
The regulation of the content of the progesterone receptor in the breast of many species including the mouse is under the control of estrogen (21, 22) , and therefore, we designed experiments to study the interaction of androgen and estrogen on the breast progesterone receptor. The sucrose density gradient analysis of the binding of the synthetic progestogen, [3H]promegestone, in cytosol of mouse breast is illustrated in Fig. 3 . As previously described by Haslam Table I ). As in female mice, castration causes disappearance of the progesterone receptor from the breast of the tfm mouse, and estradiol implants cause a doubling of the level of the receptor as compared with the intact control. Dihydrotestosterone inhibits the estradiol-mediated increase in the progesterone receptor similarly in the tfm and control animals. The fact that maximal level of receptor in this experiment is less than that of the CBA/J mice is probably a consequence of the genetic background (C57BL/J mice) upon which the ta and tfm mutations are carried rather than a consequence of the mutations themselves. Therefore, we repeated the experiment in F, crosses between CBA/J males and inbred females carrying the ta and tfm mutations (experiment 2, Table I ). Once again, the antiestrogenic action of dihydrotestosterone was similar in control females and in the tfm males. We concluded that the antiestrogenic action of dihydrotestosterone in these mice is not mediated by the androgen receptor. We then examined the possibility that dihydrotestosterone acts as an antiestrogen at the level of the estrogen receptor. mg/ml. (Table II) .
Since some estrogen antagonists that bind to the estrogen receptor have the capacity to anchor the cytoplasmic receptor in the nucleus, we then investigated the effect of 2 wk of dihydrotestosterone treatment on the intracellular distribution of the estradiol receptor in mouse breast (Fig. 7) . In the preparation from the animals that had received dihydrotestosterone, more estradiol receptor was recovered in the nuclear fraction than in the cytosol, but there was no effect on the total amount of estradiol receptor recovered (cytoplasmic plus nuclear).
Discussion
In hopes that an animal model might provide insight into the pathogenesis of gynecomastia in men, we have investigated the interaction of androgen and estrogen in the breast of the mouse. The mouse was utilized because of the availability of the tfm mouse which lacks a functional androgen receptor (24) . Therefore, we utilized the breast of the virgin female mouse for these studies.
Estrogen treatment to such mice stimulates breast growth and as in other species increases the amount of progesterone receptor in the breast. Both effects of estradiol can be inhibited by dihydrotestosterone. We concluded that this might be an adequate model system for investigating the mechanism of the antiestrogenic action of androgen, and we designed experiments to assess two mechanisms that have been proposed for this action, namely that androgen acts at the genomic level via its own receptor to block estrogen action or that androgen acts as a pharmacological antagonist and/or weak estrogen agonist by competing with estradiol for the estrogen receptor. The findings in these experiments favor the latter possibility. Indeed, the fact that dihydrotestosterone was equally effective in blocking estrogen effects in tfm/Y and control mice suggests that this action of androgen is not mediated by the androgen receptor. If this interpretation is correct, then this effect of androgen is different than the antiestrogenic effect of the hormone in the embryonic mouse breast (11) and in the uterus (12).
Dihydrotestosterone binds weakly to the estrogen receptor in mouse breast and like some other antiestrogens appears to anchor the estrogen-receptor in the nucleus of the cell. These effects have only been studied with pharmacological amounts of hormone, but the fact that the relative binding affinities of dihydrotestosterone, 313-androstanediol, testosterone, and Sfdihydrotestosterone correlate with their capacities to inhibit induction of the progesterone receptor is in keeping with the finding in MCF7 tumor cells (10) that androgens bind to the estrogen receptor. Unlike the situation in MCF7 cells, however, we were unable to demonstrate any estrogen-like effects of dihydrotestosterone on the mouse breast. Demonstration that this model system provides insight into the estrogen-androgen interaction in the human breast will require additional studies of several types. First, the concentration of hormones at which androgen antagonizes estrogen action in the human is within the physiological range and it may be necessary to perform long-term studies in mice using smaller implants to determine whether this system is in fact analogous to the human breast. In addition, levels of androgens and estrogens in the breast and in plasma will have to be carefully monitored. Second, these findings leave unexplained the failure of the breast to feminize in men with 5a-reductase deficiency (25) ; namely, we found that testosterone is a weaker antagonist of estrogen in mouse breast than is dihydrotestosterone and it would logically follow that when dihydrotestosterone formation is impaired in the face of normal estrogen formation and action, the breasts might enlarge. However, there appears to be a species variability in that the human estrogen receptor binds testosterone and dihydrotestosterone with similar affinities (10), and consequently, it is possible that in the human male testosterone and dihydrotestosterone are equally effective antagonists of estrogen. Again, this phenomenon will have to be investigated in receptors derived from human breast. Third, it has been generally assumed, certainly by us, that feminization of the breasts in human subjects with defective androgen receptor (testicular feminization [complete and incomplete] and the Reifenstein syndrome) is in large part due to androgen resistance (25) . However, estrogen production is also increased in these states, and it may be that estrogen itself is the primary determinant of breast enlargement in these disorders (1) .
If androgen prevents the development of gynecomastia in normal men by acting as a direct antiestrogen at the level of the estrogen receptor, this is the first androgen action recognized that is not mediated by the androgen receptor.
